Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: A systematic review

AIDS Reviews

Volumn 15, Issue 3, 2013, Pages 152-161

  Stam, Arjen J ^a   Nijhuis, Monique ^a   Van Den Bergh, Walter M ^b   Wensing, Annemarie M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cerebrospinal fluid; Compartment; CSF; Env; HIV 1; Plasma; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COPY NUMBER VARIATION; GENETIC VARIABILITY; GENOTYPE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MICROBIAL POPULATION DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PLASMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SYSTEMATIC REVIEW; VIRAL TROPISM; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY; RNA, VIRAL; VIRAL TROPISM;

EID: 84890345789     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Miller F, Afonso P, Gessain A, Ceccaldi P. Blood-brain barrier and retroviral infections. Virulence. 2012;3:222-9.
2. Eugenin E, Clements J, Zink M, Berman J. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci. 2011;31:9456-65.
3. Koenig S, Gendelman H, Orenstein J, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233:1089-93.
4. Wiley C, Schrier R, Nelson J, Lampert P, Oldstone M. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA. 1986;83:7089-93.
5. Peudenier S, Hery C, Montagnier L, Tardieu M. Human microglial cells: characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection. Ann Neurol. 1991;29:152-61.
6. Weidenheim K, Epshteyn I, Lyman W. Immunocytochemical identification of T-cells in HIV-1 encephalitis: implications for pathogenesis of CNS disease. Mod Pathol. 1993;6:167-74.
7. Takahashi K, Wesselingh S, Griffin D, McArthur J, Johnson R, Glass J. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996;39:705-11.
8. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286:1353-7.
9. Jones M, Bell J, Nath A. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS. 2000;14:2709-13.
10. Strain M, Letendre S, Pillai S, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol. 2005;79:1772-88.
11. Thomas E, Dunfee R, Stanton J, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology. 2007;360:105-19.
12. Arrildt K, Joseph S, Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep. 2012;9:52-63.
13. Verani A, Pesenti E, Polo S, et al. CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates. J Immunol. 1998;161:2084-8.
14. Karlsson U, Antonsson L, Ljungberg B, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS. 2012;26:1739-44.
15. Schnell G, Joseph S, Spudich S, Price R, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011;7:e1002286.
16. Duncan C, Sattentau Q. Viral determinants of HIV-1 macrophage tropism. Viruses. 2011;3:2255-79.
17. Gorry P, Bristol G, Zack J, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol. 2001;75:10073-89.
18. Holman A, Gabuzda D. A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia. PLoS One. 2012;7:e49538.
19. Choi J, Hightower G, Wong J, et al. Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012;18:81-90.
20. Antinori A, Perno C, Giancola M, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005;41:1787-93.
21. Letendre S, Ellis R, Ances B, McCutchan J. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
22. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19:137-42.
23. Minuesa G, Purcet S, Erkizia I, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther. 2008;324:558-67.
24. Ellis R, Gamst A, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54:927-36.
25. Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13:1051-61.
26. Heaton R, Franklin D, Ellis R, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
27. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2011;8:54-61.
28. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819-25.
29. McCarty E, Quah S, Dinsmore W, Emerson C. A case of multidrug resistance in the central nervous system. Int J STD AIDS. 2010;21:777-9.
30. Peluso M, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well-controlled plasma viral load. AIDS. 2012;26:1765-74.
31. Tamarit Mdel P, Quereda C, Gonzalez-Rozas M, Corral I, Casado J. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:83-6.
32. van Lelyveld S, Nijhuis M, Baatz F, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis. 2010;50:387-90.
33. Watanabe K, Honda M, Watanabe T, et al. Emergence of raltegravir- resistant HIV-1 in the central nervous system. Int J STD AIDS. 2010;21:840-1.
34. Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS. 2011;22:608-9.
35. Cornelissen M, Back N, Burger D, et al. Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy. Antivir Ther. 2011;16:931-5.
36. Canestri A, Lescure F, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773-8.
37. Cinque P, Presi S, Bestetti A, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses. 2001;17:377-83.
38. Bergroth T, Ekici H, Gisslen M, Hagberg L, Sonnerborg A. Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. HIV Med. 2009;10:111-15.
39. Bestetti A, Presi S, Pierotti C, et al. Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol. 2004;10(Suppl 1):52-7.
40. Caragounis E, Gisslen M, Lindh M, et al. Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected antemortem and post-mortem. Acta Neurol Scand. 2008;117:108-16.
41. Lanier E, Sturge G, McClernon D, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 2001;15:747-51.
42. McCoig C, Castrejon M, Castano E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr. 2002;141:36-44.
43. Ritola K, Robertson K, Fiscus S, Hall C, Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 2005;79:10830-4.
44. Harrington P, Schnell G, Letendre S, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009;23:907-15.
45. Schnell G, Price R, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84:2395-407.
46. Parisi S, Andreoni C, Sarmati L, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol. 2011;49:1441-5.
47. Spudich S, Nilsson A, Lollo N, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis. 2005;5:98.
48. Hightower G, Letendre S, Cherner M, et al. Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology. 2009;394:243-8.
49. Soulie C, Tubiana R, Simon A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr. 2009;51:60-4.
50. Price R, Parham R, Kroll J, et al. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther. 2008;13:369-74.
51. Spudich S, Lollo N, Liegler T, Deeks S, Price R. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194:1686-96.
52. Brew B, Pemberton L, Ray J. Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs? J Neurovirol. 2004;10(Suppl 1):38-43.
53. Eggers C, Hertogs K, Sturenburg H, van Lunzen J, Stellbrink H. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS. 2003;17:1897-906.
54. Tashima K, Flanigan T, Kurpewski J, Melanson S, Skolnik P. Discordant human immunodeficiency virus type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. Clin Infect Dis. 2002;35:82-3.
55. Stingele K, Haas J, Zimmermann T, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology. 2001;56:355-61.
56. Cunningham P, Smith D, Satchell C, Cooper D, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000;14:1949-54.
57. Tang Y, Huong J, Lloyd R, Spearman P, Haas D. Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J Clin Microbiol. 2000;38:4637-9.
58. Venturi G, Catucci M, Romano L, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis. 2000;181:740-5.
59. Chien J, Valdez H, McComsey G, McClernon D, St Clair M, Lederman M. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. J Acquir Immune Defic Syndr. 1999;21:277-80.
60. Karlsson U, Antonsson L, Repits J, et al. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retroviruses. 2009;25:1297-305.
61. Smith D, Zarate S, Shao H, et al. Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology. 2009;385:204-8.
62. Pillai S, Pond S, Liu Y, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain. 2006;129:1872-83.
63. Abbate I, Cappiello G, Longo R, et al. Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. Infect Genet Evol. 2005;5:247-53.
64. Briggs D, Tuttle D, Sleasman J, Goodenow M. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2000;14:2937-9.
65. Hung C, Vander Heyden N, Ratner L. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol. 1999;73:8216-26.
66. Di Stefano M, Monno L, Fiore J, et al. Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS. 1998;12:737-43.
67. Kuiken C, Goudsmit J, Weiller G, et al. Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex. J Gen Virol. 1995;76:175-80.
68. de Jong J, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol. 1992;66:757-65.
69. Fouchier R, Groenink M, Kootstra N, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol. 1992;66:3183-7.
70. Keys B, Karis J, Fadeel B, et al. V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. Virology. 1993;196:475-83.